Mavacamten (camzyos) and pomalidomide (polmalyst)
Ended Awarded Last action
- Contract number
- 36C24526N0290
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $371,280
Award facts
- Contract value 100% obligated
- $371,280.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $6,164 | |
| Supplemental Agreement for work within scope | $8,573 | |
| Original award | $356,543 |
About this award
The Veterans Integrated Service Network 5 issued a BPA call to Bristol-Myers Squibb Company on January 29, 2026, for MAVACAMTEN (CAMZYOS) and POMALIDOMIDE (POMALYST) with a ceiling value of $371,280.32 under the Pharmaceuticals and Drugs (FSS-61-IB) GSA Federal Supply Schedule.
Place of performance is Memphis, Tennessee. The call is firm fixed price and extends through September 30, 2026. This order procures two specialized pharmaceutical agents: CAMZYOS, indicated for hypertrophic cardiomyopathy, and POMALYST, an immunomodulatory agent used in hematologic malignancies and oncology treatment protocols. The GSA schedule parent vehicle is a multiple-award IDIQ with a $12.278 billion ceiling through April 30, 2029.
Quick answers
Who was awarded contract 36C24526N0290?
36C24526N0290 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on January 29, 2026.
How much is contract 36C24526N0290 worth?
The government has obligated $371,280 on 36C24526N0290.
Is contract 36C24526N0290 an order under another contract?
Yes. 36C24526N0290 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0290 competed?
The extent of competition for 36C24526N0290 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award